News & Updates

PDE5 inhibitor plus nitrates do not induce adverse events in IHD patients

29 Apr 2022

Use of phosphodiesterase type 5 (PDE5) inhibitors has increased 20-fold from 2000 to 2018, according to a study of Danish patients with ischaemic heart disease (IHD) who were taking nitrates. In addition, no statistically significant association has been observed between concomitant use of PDE5 inhibitors and cardiovascular adverse events.

PDE5 inhibitor plus nitrates do not induce adverse events in IHD patients

29 Apr 2022

Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer

29 Apr 2022 by

In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.

Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer

29 Apr 2022

Dupilumab stops the itch, clears skin lesions in phase III trial

29 Apr 2022 by

The human monoclonal IgG4 antibody dupilumab effectively treats prurigo nodularis (PN), including itching and skin lesions, weeks after treatment in the phase III randomized, double-blind, LIBERTY-PN PRIME2 trial. Hopefully, this brings relief to patients suffering from uncontrolled PN.

Dupilumab stops the itch, clears skin lesions in phase III trial

29 Apr 2022

Calorie restriction, with or without restricted eating, shows similar effects on weight loss

29 Apr 2022 by

Daily calorie restriction, regardless of whether or not eating was time-restricted between 8:00 am and 4:00 pm, showed similar effects on weight loss in patients with obesity, according to a recent study.

Calorie restriction, with or without restricted eating, shows similar effects on weight loss

29 Apr 2022

CV risk elevated following cancer diagnosis

28 Apr 2022 by

Patients newly diagnosed with cancer have an increased risk of cardiovascular (CV) events including CV mortality, according to a retrospective population-based study from Canada.

CV risk elevated following cancer diagnosis

28 Apr 2022

Intravenous steroids help prevent surgery in lumbar disc herniation patients with radiculopathy

28 Apr 2022

In patients with lumbar disc herniation and intractable radicular pain, the use of intravenous steroid treatment can help reduce the need for surgery, reports a recent study.

Intravenous steroids help prevent surgery in lumbar disc herniation patients with radiculopathy

28 Apr 2022

Should intraperitoneal chemo be reconsidered for ovarian cancer?

28 Apr 2022 by

Progression-free survival (PFS) is significantly longer with intraperitoneal (IP) over intravenous (IV) carboplatin, when combined with dose-dense paclitaxel, in patients with ovarian, fallopian tube, or primary peritoneal cancer, regardless of residual tumour size after initial surgery, according to the phase III iPocc* trial presented at SGO 2022.

Should intraperitoneal chemo be reconsidered for ovarian cancer?

28 Apr 2022

Brain implant succeeds in amyotrophic lateral sclerosis

28 Apr 2022 by

Implantation with a motor neuroprosthesis, an endovascular brain-computer interface, appears to be safe in amyotrophic lateral sclerosis (ALS) patients with paralysis and helps them operate a computer for daily tasks, according to a study presented at the American Academy of Neurology’s (AAN) Annual Meeting.